RXi, the RNAi subsidiary of CytRx, has named Dmitry Samarsky as its vice president of technology development.
Samarsky was most recently director of technology development at Dharmacon, a unit of Thermo Fisher Scientific. Prior to that, he was business development manager at Invitrogen.
Earlier in his career, Samarsky held various business development roles at Sequitur, an RNAi reagent company acquired by Invitrogen and founded by RXi’s president and CEO, Tod Woolf.
Samarsky holds a PhD in biochemistry and molecular biology from the University of Massachusetts, Amherst.
Adenosine Therapeutics has appointed Steven Tregay to its board of directors.
Tregay is a managing director of the Novartis Option Fund and was recently named a director of Cequent Pharmaceuticals.